| 178.75 0 (0%) | 04-24 15:47 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
Acceleron Pharma Inc. is a biopharmaceutical firm dedicated to discovering, advancing, and bringing to market treatments for severe and uncommon illnesses. Its flagship product, REBLOZYL (luspatercept-aamt), addresses anemia in adult patients afflicted with beta-thalassemia. The company's pipeline includes additional applications for luspatercept-aamt targeting myelodysplastic syndromes and myelofibrosis. Furthermore, it is developing Sotatercept for patients suffering from pulmonary arterial hypertension. A neuromuscular therapeutic candidate, ACE-083, is currently undergoing Phase II clinical trials to treat Charcot-Marie-Tooth disease. Acceleron has also forged strategic alliances, including a collaboration, license, and option pact with Celgene Corporation. Another partnership with Fulcrum Therapeutics, Inc. focuses on a collaboration and license agreement to pinpoint small molecules capable of modulating particular pathways relevant to specific pulmonary conditions. Initially established in 2003 as Phoenix Pharma, Inc., the company, now known as Acceleron Pharma Inc., maintains its headquarters in Cambridge, Massachusetts.
Fri, 22 Nov 2024
Tom Maniatis Net Worth (2026) - GuruFocus
Tue, 06 Aug 2024
Acceleron Pharma Inc (XLRN:UQ): Stock Price, Quote and News - bnnbloomberg.ca
Mon, 21 Nov 2022
Merck & Co to Acquire Imago BioSciences for $1.35 Billion - equitypandit.com
Thu, 30 Sep 2021
Merck to buy Acceleron for about $11.5 bln in rare disease drug push - Reuters
Mon, 27 Sep 2021
Merck in advanced talks to buy Acceleron Pharma - WSJ - Reuters
Wed, 21 Apr 2021
xlrn-20201231 - SEC.gov
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |
|
|
|
|
|
|
|
|
|